Skip NavigationSkip to Content
Loading

Antibody Characterization Laboratory (ACL)

Developing and characterizing antigens and antibodies for distribution to the research community

Laboratory Overview

The Antibody Characterization Laboratory (ACL) is the laboratory responsible for the development of well-characterized monoclonal antibody reagents. The NCI’s Office of Cancer Clinical Proteomics Research funds ACL as a resource to the entire cancer research community. ACL produces monoclonal antibodies to putative cancer targets selected by an Antibody Scientific Committee, and each antibody is characterized using optimized Standard Operating Procedures (SOPs). Approximately twice a year there is a reagent target request open to the extramural research community. Interested researchers, with readily available protein/peptides submit a request using an online form.  To find out more information about the target request and the currently available data visit the Antibody portal at http://antibodies.cancer.gov/.

Antibody Characterization:

The ACL engages in characterization of monoclonal antibodies using an SOP-driven set of standard assays that provide baseline understanding of the performance of antibodies in a variety of different assays including: SDS-PAGE, Western blot, ELISA, Immunohistochemistry, Immuno Mass Spectroscopy and Surface Plasmon Resonance.

Antibody Portal

Characterization Data Available:

Antibody characterization data is publicly available at http://antibodies.cancer.gov and is provided to help accelerate cancer research.

Figure with two histograms and one graph of typical immuno-assays

Monoclonal Antibodies and Cell Lines Available:

Monoclonal antibodies and hybridomas are available at the Developmental Studies Hybridoma Bank (http://dshb.biology.uiowa.edu/) for research use only and to commercial entities through non-exclusive licensing agreements for more information contact cancer.proteomics@mail.nih.gov.

ACL Expertise in Immunoassay Development:

ACL staff have expertise in development of immunoassay and are available for consultation.  Expertise includes: Design, development, and deployment of FDA-approved assay;  cGMP design of reagents and documentation;  Clinical laboratory operation and management; Antibody selection and pairing.

Page last updated January 22, 2013 @ 8:02 am